DEMONSTRATION DATA·NO PHI
Phase 2 · Retrospective

What Kairos would have caught

Looking back at the past 6 months on the panel: where the signals were present, how early they were detectable, and what proactive contact would have been worth.

Past 6 months · 47-patient panel
4
HF readmissions
across the panel
3
had detectable early warning
in chart data already on file
9d
average lead time
from earliest signal to admission
3
estimated preventable
with proactive nurse contact

One of the four readmissions had no detectable prodrome, a true unpredictable event. The other three are below.

Case detail

Three readmissions, three signals, what would have changed

James O'Brien
81 M
Lead 9 days
Admission
2026-03-22 · Acute on chronic HF exacerbation
Signal in the chart

Daughter's MyChart message at day 25 post-discharge matched the prodrome signature from his prior three admissions: fatigue plus reduced PO intake without overt edema.

What would have caught it

Same-week proactive nurse callback before symptoms progressed. Pattern was deterministic: three prior prodromes, all in the same post-discharge window.

TodayInsight live on the panel today. Outreach drafted; visit not yet rescheduled.
Eleanor Howell
76 F
Lead 8 days
Admission
2025-11-14 · Decompensated HFpEF with AKI
Signal in the chart

Home weight log showed a 4-pound gain over 72 hours at day 17 post-discharge; coincided with a 5-day gap in furosemide refill on the pharmacy feed.

What would have caught it

Cross-source signal joining vitals + pharmacy refill. Neither alone met threshold; together they did.

TodaySignal not surfaced at the time. Patient self-presented to the ED 8 days later.
Frank Delgado
79 M
Lead 10 days
Admission
2026-01-08 · HFrEF + COPD overlap exacerbation
Signal in the chart

Home pulse-ox feed (Bluetooth) trended from 94% baseline to 89% over 6 days. Tiotropium adherence dropped to 40% over the same window.

What would have caught it

Adherence-weighted vitals trend, catching the SpO2 drift in the context of a known COPD adherence dip.

TodaySignal not surfaced at the time. Patient called clinic on day 10 and was sent to ED.

Guideline gap analysis

Panel-wide opportunities flagged against current society guidelines

SGLT2 inhibitor: not prescribed despite eligibility
3

HFrEF + adequate eGFR meets Class 1a recommendation per 2022 AHA/ACC HF guidelines.

ARNI: not prescribed despite eligibility
2

EF ≤ 40% on ACE-I; guideline-preferred substitution for mortality benefit if tolerated.

Statin: below guideline dose intensity
4

High-risk ASCVD on low/moderate-intensity statin where high-intensity is indicated.

Annual labs: overdue
6

Last lipid / CMP / HbA1c outside the 14-month surveillance window for actively managed conditions.

Intervention success rate

Across 12 interventions on the 5 detailed patients

2
3
3
4
On track2 · 17%
Partial response3 · 25%
Pending follow-up3 · 25%
Missed expected outcome4 · 33%

"Missed" means the documented expected outcome did not occur and no follow-up intervention was attempted. Most of these are the moments Kairos surfaces as actionable insights on the panel today.

Aggregates are computed at render time from data/patients.json. Demonstration data: fictional patients, no PHI. Drill-through to the underlying cohort is on the Phase 3 roadmap.